US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| AGRYLIN | EQ 0.5MG BASE | capsule · oral | TAKEDA PHARMS USA | Prescription | 14 Mar 1997 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | CIPLA | Prescription | 18 Apr 2005 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | NOVITIUM PHARMA | Prescription | 18 Apr 2005 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | IMPAX LABS | Prescription | 18 Apr 2005 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | TORRENT | Prescription | 30 Jun 2017 |
| AGRYLIN | EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | TAKEDA PHARMS USA | Discontinued | 14 Mar 1997 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | WATSON LABS | Discontinued | 18 Apr 2005 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | ROXANE | Discontinued | 18 Apr 2005 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | BARR LABS | Discontinued | 18 Apr 2005 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | CHARTWELL RX | Discontinued | 18 Apr 2005 |
| ANAGRELIDE HYDROCHLORIDE | EQ 0.5MG BASE; EQ 1MG BASE | capsule · oral | RISING | Discontinued | 27 Jun 2006 |
EMA European Union — centrally authorised medicines
Xagrid Takeda Pharmaceuticals International AG Ireland · Authorised · authorised 15 Nov 2004 · ATC L01XX35
Therapeutic indication (EMA)
Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET is defined by one or more of the following features: >60 years of age or; a platelet count >1000 x 109/l or; a history of thrombohaemorrhagic events.
Therapeutic indication (EMA)
Anagrelide Viatris is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patient An at-risk essential thrombocythaemia patient is defined by one or more of the following features: >60 years of age or a platelet count >1,000 x 10⁹/l or a history of thrombo-haemorrhagic events.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| PMS-ANAGRELIDE | 02274949 | 0.5 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | ANAGRELIDE HCL 0.5 MG CAPSULE | $0.72949 | per EA | 23 Sep 2026 |
| US NADAC | ANAGRELIDE HCL 1 MG CAPSULE | $1.41317 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Anagrelide 500microgram capsules | £249.99 | 100 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.